Advanced search×

Identification of Aneuploidy-Tolerating Mutations

Cell 143(1):13 (2010) PMID 20850176 PMCID PMC2993244

Aneuploidy causes a proliferative disadvantage in all normal cells analyzed to date, yet this condition is associated with a disease characterized by unabated proliferative potential, cancer. The mechanisms that allow cancer cells to tolerate the adverse effects of aneuploidy are not known. To probe this question, we identified aneuploid yeast strains with improved proliferative abilities. Their molecular characterization revealed strain-specific genetic alterations as well as mutations shared between different aneuploid strains. Among the latter, a loss-of-function mutation in the gene encoding the deubiquitinating enzyme Ubp6 improves growth rates in four different aneuploid yeast strains by attenuating the changes in intracellular protein composition caused by aneuploidy. Our results demonstrate the existence of aneuploidy-tolerating mutations that improve the fitness of multiple different aneuploidies and highlight the importance of ubiquitin-proteasomal degradation in suppressing the adverse effects of aneuploidy.

DOI: 10.1016/j.cell.2010.08.038
Version: za2963e q8zab q8zb3 q8zc8 q8zdb q8zea q8zfe q8zg9

Similar articles you may find interesting…

  1. Abnormal Glycemic Profiles by CGMS in Obese First-Degree Relatives of Type 2 Diabetes Mellitus Patients.

    Diabetes Technol Ther (2013) PMID 23631606

    CGMS indicated the presence of significant dysglycemia in first-degree relatives of diabetes patients without diabetes who were centrally obese. Hence it could be useful for early identification of individuals at greater risk of diabetes. A deranged glycemic profile may precede onset of overt diabet...
  2. THE CHANGING MUTATIONAL LANDSCAPE OF ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME.

    Mol Cancer Res (2013) PMID 23645565

    We will discuss the most recently identified genetic abnormalities described in MDS and AML and appraise the current status quo of the dynamics of acquisition of mutant alleles in the pathogenesis of AML, during the transformation from MDS to AML, and in the context of relapse after conventional che...
  3. RBx10080307, A dual EGFR/IGF-1R inhibitor for anticancer therapy.

    Eur J Pharmacol (2013) PMID 23639757

    We report the identification of a novel, small molecule dual EGFR/IGF-1R inhibitor, RBx10080307 which displayed in vitro activity at the molecular level and oral efficacy in mouse xenograft model. The compound also showed in vitro activity in an EGFR mutant cell line and may thus have the potential...